5-year risk of cardiovascular diseases under exposure deciles of A) HbA1C-CV and B) FPG-CV. by Khadije Maajani (10125692)

Data_Sheet_1_Grape polyphenols decrease circulating branched chain amino acids in overfed adults.pdf by Simona Bartova (14011194)

Melting points of HNL1 (A & B) and <i>Hb</i>HNL (C & D). by Bryan J. Jones (7354394)

Identification of novel, small molecule TTBK1 inhibitor which dose dependently decreases tau phosphorylation at S422. by Gregory M. Dillon (8681430)

A comparative study of the toxicological aspects of vanadium pentoxide and vanadium oxide nanoparticles by Apoorva Kulkarni (1287453)

“…V₂O₅ and VO₂ NPs exhibited rod and spherical symmetry, respectively with a mean diameter of 50 ± 20 and 30 ± 10 nm. …”

Interpretation of bidirectional MR. by Laurence J. Howe (5579186)

Supplementary Material for: 3,4-Methylenedioxymethamphetamine (Ecstasy) Decreases Inflammation and Airway Reactivity in a Murine Model of Asthma by Stankevicius D. (4130146)

“…We also showed that MDMA decreased expression of both Th2-like cytokines (IL-4, IL-5 and IL-10) and adhesion molecules (L-selectin). …”

The intracellular calcium chelator BAPTA decreased cell retention of I-HIV at 20 uM (panel A) and increased transport rate of I-HIV at 10 uM (panel B). by Shinya Dohgu (285633)

Inhibition of Hsp90 abolished VEGF-mediated eNOS phosphorylation and decreased NO production and cell viability in BAECs. by Yuanzhuo Chen (802891)

Thermostability of <i>Hb</i>HNL and HNL1 measured by urea-induced unfolding. by Bryan J. Jones (7354394)

Exposure to EtBr decreases mtRNA in rat striatal co-cultures, purified neuronal cultures, and astrocytes. by Emily Booth Warren (4276333)

“…<p>(A-C) Log2-fold decrease in mtRNA expression after EtBr treatment assayed with RNASeq, in (A) NECos, (B), pure neuronal cultures, and (C) astrocytes. …”

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Decrease in sterol accumulation in NPC1 mutant cells expressing TgNCR1-hNPC1. by Bao Lige (113279)

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”